Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVIDGlobeNewsWire • 03/26/24
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 02/29/24
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming MilestonesGlobeNewsWire • 02/28/24
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVIDGlobeNewsWire • 01/22/24
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVIDGlobeNewsWire • 01/02/24
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/13/23
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023GlobeNewsWire • 11/06/23
Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023GlobeNewsWire • 10/12/23
Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023GlobeNewsWire • 09/12/23
Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/10/23
Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for FibromyalgiaGlobeNewsWire • 08/09/23
Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept StudyGlobeNewsWire • 07/17/23
Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewsWire • 05/25/23
Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat FibromyalgiaGlobeNewsWire • 05/15/23
Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023GlobeNewsWire • 05/04/23
Virios Therapeutics stock doubles as fibromyalgia program moves forwardProactive Investors • 04/25/23
Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of FibromyalgiaGlobeNewsWire • 04/24/23